Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J/Bayer’s Rivaroxaban Clinical Program Reports Few Liver Toxicity Cases

This article was originally published in The Pink Sheet Daily

Executive Summary

Oral Factor Xa inhibitor will be filed mid-year for prevention of venous thromboembolism in orthopedic surgery patients.

You may also be interested in...



Safety Results Prompt Bristol To Refine Apixaban Dosing In Acute Coronary Syndrome Trials

Firm is discussing Phase III design with regulators.

Safety Results Prompt Bristol To Refine Apixaban Dosing In Acute Coronary Syndrome Trials

Firm is discussing Phase III design with regulators.

With European Approval Imminent, J&J/Bayer File Rivaroxaban In The U.S.

Novel anticoagulant for orthopedic surgery poised to reach market before Pfizer, Bristol, Astellas and Daiichi Sankyo compounds.

Topics

UsernamePublicRestriction

Register

LL1135645

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel